EXTH-64. RAPID IN SITU GEL-FORMING BY LIGHT-IRRADIATION FOR COMBINATION OF CHEMOTHERAPY AND RADIOTHERAPY IN BRAIN TUMOR

摘要

About 40,000 people are diagnosed with primary brain tumors in the United States each year, an estimated 15,000 have glioblastoma multiforme (GBM), which is still associated with poor prognosis with 14.6 month of median survival after surgical resection combined with chemotherapy and radiation. Preventing tumor recurrence after surgical resection of a brain tumor is a significant clinical challenge because current methods deliver chemotherapeutic agents in a rapid manner and are not effective against the residual tumor cells, such as Gliadel^®. To overcome this drawback, we develop a rapid gelled hydrogel which can tightly adhere on the tissues for controlled chemotherapy, radiotherapy, and enhanced laser interstitial thermal therapy (LITT) to improve the survival after surgical resection. The principle goals are to i) determine the prevailing factors that affect efficient encapsulation of chemotherapeutic drugs (i.e., Epirubicin or Temozolomide) and radio-sensitizer (i.e., Cisplatin) within hydrogels, ii) demonstrate efficiency of gelation, LITT enhancement, in vitro drug release, iii) evaluate the efficiency in human cancer cells and in vivo tumor model. Our preliminary results have successfully demonstrated the feasibility of this grant and our materials design. We believe this synergistic strategy presents a new approach to the development of a local drug delivery system for the prevention of brain tumor recurrence.